申请人:SMITH KLINE & FRENCH LABORATORIES
LIMITED
公开号:EP0395328A2
公开(公告)日:1990-10-31
Compounds of the formula (1) :
and pharmaceutically acceptable salts thereof are described wherein R¹ is C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₅cycloalkylC₁₋₆alkyl, phenylC₁₋₆alkyl or C₁₋₆alkyl substituted by 1 to 6 fluoro groups; and R² is C₁₋₆alkyl, phenyl, hydroxy, C₁₋₆alkoxy, halo, -NHCOR³, -NHCONHR⁴, 5-tetrazolyl, -CO₂R⁵, cyano, -CONR⁶R⁷, or -NR⁸R⁹ wherein R³ to R⁷ are independently hydrogen or C₁₋₆alkyl and R⁸ and R⁹ are independently hydrogen or C₁₋₆alkyl optionally substituted by hydroxy provided that the carbon atom adjacent to the nitrogen atom is not substituted by hydroxy.
Processes for their preparation, pharmaceutical compositions comprising them and their use as medicaments are also described.
式 (1) :
及其药学上可接受的盐,其中 R¹ 是 C₁₋₆烷基、C₂₋₆烯基、C₃₋₅烷基、苯基C₁₋₆烷基或被 1 至 6 个氟基团取代的 C₁₋₆ 烷基;而 R² 是 C₁₋₆烷基、苯基、羟基、C₁₋₆烷氧基、卤代、-NHCOR³、-NHCONHR⁴、5-四唑基、-CO₂R⁵、氰基、-CONR⁶R⁷、或-NR⁸R⁹,其中 R³ 至 R⁷ 独立地为氢或 C₁₋₆alkyl,R⁸ 和 R𠞙 独立地为氢或 C₁₋₆alkyl 可选地被羟基取代,条件是与氮原子相邻的碳原子未被羟基取代。
此外,还描述了它们的制备工艺、包含它们的药物组合物以及它们作为药物的用途。